Chiesi USA, Inc. drugs
7 results
Cleviprex (clevipidine)
(clevipidine)Chiesi USA, Inc.
Usage: Cleviprex is indicated for reducing blood pressure in patients when oral therapy is not feasible or desirable.
Elfabrio (pegunigalsidase alfa)
(pegunigalsidase alfa)Chiesi USA, Inc.
Usage: ELFABRIO is indicated for the treatment of adults with confirmed Fabry disease, a genetic disorder that affects various bodily systems due to a deficiency in the enzyme alpha-galactosidase A.
Ferriprox (deferiprone)
(deferiprone)Chiesi USA, Inc.
Usage: FERRIPROX Tablets are indicated for treating transfusional iron overload in adults and pediatric patients (8 years and older) with thalassemia syndromes, sickle cell disease, or other anemias. Safety and effectiveness are not established for use in myelodysplastic syndrome or Diamond Blackfan anemia.
Kengreal (cangrelor)
(cangrelor)Chiesi USA, Inc.
Usage: KENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction, repeat coronary revascularization, and stent thrombosis in patients not treated with a P2Y12 platelet inhibitor and not receiving a glycoprotein IIb/IIIa inhibitor.
Lamzede (velmanase alfa-tycv)
(Velmanase alfa-tycv)Chiesi USA, Inc.
Usage: LAMZEDE is indicated for treating non-central nervous system manifestations of alpha-mannosidosis in both adult and pediatric patients.
Retavase (reteplase)
(reteplase)Chiesi USA, Inc.
Usage: RETAVASE is indicated for the treatment of acute ST-elevation myocardial infarction (STEMI) to decrease the risk of death and heart failure. However, thrombolytic therapy may not be beneficial in low-risk STEMI patients due to the potential increased risk of stroke.
Revcovi (elapegademase-lvlr)
(elapegademase-lvlr)Chiesi USA, Inc.
Usage: REVCOVI is indicated for treating adenosine deaminase severe combined immune deficiency (ADA-SCID) in both pediatric and adult patients.